Charles River Laboratories Intl. (CRL) PT Raised to $148.00 at Robert W. Baird

Charles River Laboratories Intl. (NYSE:CRL) had its target price upped by stock analysts at Robert W. Baird from $144.00 to $148.00 in a research report issued on Thursday. The brokerage currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target indicates a potential upside of 8.46% from the stock’s current price.

Several other research analysts have also recently weighed in on CRL. Bank of America upped their price objective on Charles River Laboratories Intl. from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Monday, July 16th. ValuEngine raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research report on Wednesday, July 18th. Royal Bank of Canada set a $147.00 price objective on Charles River Laboratories Intl. and gave the stock a “buy” rating in a research report on Wednesday. Jefferies Financial Group upped their price objective on Charles River Laboratories Intl. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Finally, SunTrust Banks upped their price objective on Charles River Laboratories Intl. to $135.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $130.56.

CRL stock opened at $136.45 on Thursday. The company has a quick ratio of 1.48, a current ratio of 1.72 and a debt-to-equity ratio of 1.52. The stock has a market cap of $6.54 billion, a PE ratio of 25.89, a PEG ratio of 1.71 and a beta of 0.74. Charles River Laboratories Intl. has a fifty-two week low of $96.70 and a fifty-two week high of $138.89.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings data on Wednesday, November 7th. The medical research company reported $1.53 earnings per share for the quarter, topping the consensus estimate of $1.38 by $0.15. The company had revenue of $585.30 million during the quarter, compared to analysts’ expectations of $567.58 million. Charles River Laboratories Intl. had a return on equity of 25.81% and a net margin of 6.39%. Charles River Laboratories Intl.’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.30 earnings per share. As a group, equities research analysts anticipate that Charles River Laboratories Intl. will post 5.93 EPS for the current fiscal year.

In related news, insider David P. Johst sold 23,356 shares of the company’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $136.00, for a total transaction of $3,176,416.00. Following the sale, the insider now owns 219,849 shares in the company, valued at $29,899,464. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Ross Smith sold 1,249 shares of the company’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $120.05, for a total value of $149,942.45. Following the sale, the insider now owns 13,690 shares in the company, valued at approximately $1,643,484.50. The disclosure for this sale can be found here. Insiders have sold 28,671 shares of company stock worth $3,829,160 in the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NumerixS Investment Technologies Inc bought a new stake in Charles River Laboratories Intl. during the second quarter worth about $122,000. Wsfs Capital Management LLC bought a new stake in Charles River Laboratories Intl. in the second quarter valued at approximately $203,000. CIBC Private Wealth Group LLC bought a new stake in Charles River Laboratories Intl. in the second quarter valued at approximately $212,000. Dynamic Technology Lab Private Ltd bought a new stake in Charles River Laboratories Intl. in the second quarter valued at approximately $212,000. Finally, Visionary Asset Management Inc. bought a new stake in Charles River Laboratories Intl. in the second quarter valued at approximately $214,000. Institutional investors and hedge funds own 96.93% of the company’s stock.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Read More: Marijuana Stocks Future Looks Bright

Analyst Recommendations for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply